Clascoterone vs Glow Blend
Side-by-side comparison of Clascoterone and Glow Blend: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Clascoterone
Glow Blend
Clascoterone
Clascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S. Food and Drug Administration in…
No vendor price on file.
Full Clascoterone profileGlow Blend
GHK-Cu + BPC-157 + TB-500 blend for skin and recovery
Lowest listed price: $99.99 across 3 listings
Full Glow Blend profileSide-by-side comparison
| Attribute | Clascoterone | Glow Blend |
|---|---|---|
| Category | Pharmaceutical | Recovery |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | Clascoterone's mechanism of action is competitive antagonism of androgen receptors (AR) in cutaneous target tissues — specifically the sebocytes of sebaceous glands and the dermal papilla cells of hair follicles — combined with rapid systemic hydrolysis to the… | Glow Blend is a fixed combination of three research peptides, so its proposed effects are simply the sum of what each component does on its own - there is no unique "blend" mechanism, and no pharmacology study has ever been run on the three together. Each part… |
| Half-Life | — | Varies by component - the blend has no single half-life. BPC-157 and the TB-500 (thymosin beta-4) fragment are small peptides cleared over hours; GHK-Cu is a short-lived tripeptide-copper complex. Community dosing frequency is driven by empirical practice, not by measured pharmacokinetics of the blend. |
| Typical Dose Range | — | Blend - stated per component: GHK-Cu 1000-2000 mcg/day; BPC-157 250-500 mcg/dose; TB-500 2000-2500 mcg/dose. No validated dose exists for the combination (Research Use Only). |
| Dosing Frequency | — | GHK-Cu once daily; BPC-157 once to twice daily; TB-500 twice weekly during the loading phase, then every 1-2 weeks for maintenance. |
| Administration | — | — |
| Side Effects | Clascoterone's side effect profile at the approved indication (1% cream twice daily to facial acne) is generally favorable — consistent with its design as a topical antiandrogen with rapid systemic inactivation — with most adverse events being mild application… | Most reported effects are local: injection-site redness, swelling, itching, bruising or transient pain, plus mild skin sensitivity. GHK-Cu injections can sting, and with prolonged high-dose systemic use there is a theoretical concern for copper accumulation.… |
| Molecular Weight | — | — |
| Common Vial Sizes | — | — |
Price tracking
Clascoterone: potential benefits
- No structured benefit list published.
Glow Blend: potential benefits
- Improved skin firmness and elasticity - GHK-Cu raised collagen and elastin and improved aged-skin firmness in controlled cosmetic studies [PMID:18644225]
- Reduced appearance of fine lines and photodamage (GHK-Cu cosmetic data) [PMID:18644225]
- Support for wound and connective-tissue repair - GHK-Cu and BPC-157 accelerated healing in animal models [PMID:8836453][PMID:30915550]
- Angiogenesis / improved local blood-vessel formation - a shared mechanism of BPC-157 and the thymosin beta-4 fragment in TB-500 [PMID:20388964][PMID:14500546]
- Faster recovery from tendon, ligament and muscle strain (BPC-157 preclinical data) [PMID:30915550]
- Anti-inflammatory and antioxidant support during recovery (GHK-Cu and thymosin beta-4) [PMID:18644225][PMID:27450738]
- Reported skin 'glow' and quicker soft-tissue recovery - community/anecdotal only, not clinically verified for the blend
Frequently asked
What's the difference between Clascoterone and Glow Blend?
Clascoterone is a pharmaceutical that clascoterone's mechanism of action is competitive antagonism of androgen receptors (ar) in cutaneous target tissues — specifically the sebocytes of sebaceous glands and the dermal…. Glow Blend is a recovery that glow blend is a fixed combination of three research peptides, so its proposed effects are simply the sum of what each component does on its own - there is no unique "blend"…. The two differ in mechanism, half-life (not reported vs Varies by component - the blend has no single half-life. BPC-157 and the TB-500 (thymosin beta-4) fragment are small peptides cleared over hours; GHK-Cu is a short-lived tripeptide-copper complex. Community dosing frequency is driven by empirical practice, not by measured pharmacokinetics of the blend.), and typical dose range.
Which has the longer half-life, Clascoterone or Glow Blend?
Clascoterone has a half-life of not reported. Glow Blend has a half-life of Varies by component - the blend has no single half-life. BPC-157 and the TB-500 (thymosin beta-4) fragment are small peptides cleared over hours; GHK-Cu is a short-lived tripeptide-copper complex. Community dosing frequency is driven by empirical practice, not by measured pharmacokinetics of the blend.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack Clascoterone and Glow Blend?
Stacking depends on mechanism overlap, safety profile, and goals. Clascoterone and Glow Blend should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Clascoterone or Glow Blend
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.